Reply by Authors

J Urol. 2020 Jul;204(1):77-78. doi: 10.1097/JU.0000000000000803.02. Epub 2020 Apr 28.

Kristina Stuopelyte^{1

2}, Rasa Sabaliauskaite², Arnas Bakavicius^{3

2

4}, Benedikta S Haflidadóttir^{5

6}, Tapio Visakorpi^{5

6}, Riina-Minna Väänänen⁷, Chintan Patel⁸, Daniel C Danila^{8

9}, Hans Lilja^{8

10

11

12}, Juozas R Lazutka¹, Albertas Ulys², Feliksas Jankevicius^{2

4}, Sonata Jarmalaite^{1

2}

¹ Institute of Biomedical Sciences, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
² National Cancer Institute, Vilnius, Lithuania.
³ Urology Centre, Vilnius University, Vilnius, Lithuania.
⁴ Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
⁵ Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
⁶ Fimlab Laboratories, Tampere University Hospital, Tampere, Finland.
⁷ Department of Biotechnology, University of Turku, Turku, Finland.
⁸ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
⁹ Department of Medicine, Weill Cornell Medical College, New York, New York.
¹⁰ Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center, New York, New York.
¹¹ Department of Translational Medicine, Lund University, Malmö, Sweden.
¹² Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Headington, Oxford, United Kingdom.

No abstract available

Publication types